- 1 Title: Sex-specific genetic loci linked to early and late onset type 2 diabetes
- 2 Short title: Sex-specific genetic loci in T2D
- 3
- 4 Jaime Berumen¹*, Lorena Orozco², Héctor Gallardo-Rincón^{3,4}*, Rosa Elba Benuto⁵,
- 5 Espiridión Ramos-Martinez¹, Fernando Rivas¹, Humberto García-Ortiz², Melissa Marin-
- 6 Medina⁵, Elizabeth Barrera¹, Eligia Juárez-Torres⁵, Anabel Alvarado Silva⁵, Luis Alberto
- 7 MartÍnez-Juárez⁴, Julieta Lomelín-Gascón⁴, Alejandra Montoya⁴, Janinne Ortega-Montiel⁴,
- 8 Diego-Abelardo Alvarez-Hernández⁴, Roberto Tapia-Conyer⁶
- 9
- 10 1. Unidad de Investigación en Medicina Experimental, Facultad de Medicina, Universidad
- 11 Nacional Autónoma de México, Ciudad de México, México.
- 12 2. Instituto Nacional de Medicina Genómica, Ciudad de México, México.
- 13 3. Universidad of Guadalajara, Health Sciences University Center, Guadalajara, Jalisco,
- 14 México
- 15 4. Fundación Carlos Slim, Ciudad de México, México.
- 16 5. Laboratorio HuellaGénica, Ciudad de México, México.
- 17 6. Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México,
- 18 México
- 19
- 20 ***Corresponding authors:**
- 21 Jaime Berumen
- 22 Unidad de Investigación en Medicina Experimental, Hospital General de México. Dr. Balmis
- 23 148, Doctores, Cuauhtémoc, 06720 Ciudad de México, CDMX, México
- 24 Phone: 52 55 1850 4023
- 25 Email: jaimeberumen47@gmail.com
- 26 Héctor Gallardo-Rincón
- 27 Fundación Carlos Slim

29	Hidalgo, 11529, México City, México
30	Phone: +52 55 4976 0344
31	Email: hgallardo@fundacioncarlosslim.org
32	
33	Support for paper writing:
34	Writing support was funded by the Fundación Carlos Slim.
35	
36	Disclosure statement:
37	H.G.R., L.A.M.J., J.L.G., A.M., J.O.M., and D.A.A.H. are employed by the
38	Fundación Carlos Slim. All other authors have nothing to disclose.
39	
40	Word count, abstract: 259
41	Word count, text: 5358

Lago Zurich 245, Presa Falcon Building (Floor 20), Col. Ampliacion Granada, Miguel

42 Number of tables/figures: 2/6

28

43 **Supplementary materials:** 14 tables

44 Abstract

45 Purpose

46 To investigate the effect of sex and age on the timing of a type 2 diabetes (T2D) diagnosis

47 and the influence T2D-related genes, parental history of T2D, and obesity on T2D

48 development.

49 Methods

In this case-control study, 1012 T2D cases and 1008 healthy subjects were selected from the Diabetes in Mexico Study database. Participants were stratified by sex and age at T2D diagnosis (early, \leq 45 years; late, \geq 46 years). Seventy T2D-associated SNPs were explored and the percentage contribution (R²) of T2D-related genes, parental history of T2D, and obesity (body mass index [BMI] and waist-hip ratio [WHR]) on T2D development was calculated using univariate and multivariate logistic regression models.

56 Results

57 T2D-related genes influenced T2D development most in males who were diagnosed early

58 ($R^2 = 23.5\%$; females diagnosed early, $R^2 = 13.5\%$; males and females diagnosed late, $R^2 =$

59 11.9% and $R^2 = 7.3\%$, respectively). With an early diagnosis, insulin production genes were

60 more influential in males (76.0% of R²) whilst peripheral insulin resistance genes were more

61 influential in females (52.3% of R²). With a late diagnosis, insulin production genes from

62 chromosome region 11p15.5 notably influenced males while peripheral insulin resistance

and inflammation genes notably influenced females. Influence of parental history was higher

- among those diagnosed early (males, 19.9%; females, 17.5%) versus late (males, 6.4%;
- 65 females, 5,3%). Unilateral maternal T2D history was more influential than paternal T2D
- history. BMI influenced T2D development for all, while WHR exclusively influenced males.

67 Conclusions

The influence of T2D-related genes, maternal T2D history, and fat distribution on T2D

69 development was greater in males than females.

70 **Keywords:** age, genetic loci, obesity, sex, type 2 diabetes, parental history

71 Introduction

72 The etiological parameters of type 2 diabetes (T2D) have not been fully elucidated; however, 73 T2D is clearly associated with obesity, parental history, genes, ethnicity, poor eating habits, 74 dyslipidemia, lack of physical activity, and aging, among others (1). Of these, obesity, 75 parental history, and genes appear most important. Obesity, a modifiable factor, is clearly 76 associated with T2D development and is considered the main risk factor; T2D risk increases 77 linearly with increased body mass index (BMI) (2-4). However, the relationship between T2D 78 and obesity may not be as direct as thought. For example, in countries such as China, India, 79 and Japan, where the prevalence of T2D is high, the prevalence of obesity is relatively low. 80 Currently, we know that approximately two-thirds of people with T2D are overweight or 81 obese; however, only 2%–13% of obese people develop T2D. When using univariate logistic 82 regression (ULR) models, we recently reported that the variability (R^2) of T2D attributed to 83 obesity would be 12.6%-14.9% (5). However, these values vary substantially in multivariate 84 logistic regression (MLR) models that include parental history of T2D and genes as variables 85 (5).

86 The importance of parental history on T2D development has been well established in 87 both family (6-8) and association studies (9). The heritability of T2D is variable, reported to 88 be around 25% in family studies (9-11) and 20% in association studies (6, 7, 12). In a casecontrol study conducted in Mexico, the R² of T2D attributed to parental history of diabetes 89 90 was 12.1%. There are currently over 400 genes with an identified association with T2D (13). 91 However, based on their low individual odds ratios (OR), most genes have very little 92 influence on the development of the disease, which can vary with different study populations. 93 Most studies suggest that genetic involvement contributes to no more than 10% of T2D 94 variability (13, 14). Recently, a study of 16 single nucleotide polymorphisms (SNPs) with the 95 highest predictive power for T2D in a Latin American population reported that only nine were 96 associated with T2D and that this contributed to only 6.5% of T2D variability (5). However, 97 as previously reported (15), this study found that parental history and genes have a greater 98 influence on T2D when it occurs before the age of 46 and that the influence of these factors

99 decreases substantially when the disease is diagnosed later in life (\geq 46 years). Furthermore, 100 this study also found an important difference in the association of genes, but not of parental 101 history, with T2D between males and females (15). Here, the R² value was much higher in 102 males than females (11.2% versus 4.1%), and given that the differences in gene association 103 between males and females have not been previously reported or have only been reported 104 for individual genes (16, 17), the differences are likely specific to the ancestry of populations 105 in Mexico, which include a mixture of different Amerindian and European ancestries.

106 In fact, in recent high-throughput studies, as part of the Slim Initiative in Genomic 107 Medicine for the Americas (SIGMA), polymorphisms strongly associated with T2D have been 108 discovered in Mexican and Latin populations that are either non-existent or very rare in 109 European populations. These polymorphisms are located in SLC16A11 (18), INS-IGF2 (19), and HNF1A (20). Here, the difference between the R² values of males and females may be 110 111 partially explained by the difference in the effect size of these genes between sexes. We 112 note that polymorphisms in well-established genes associated with T2D in multiple 113 populations, such as KCNQ1 and TCF7L2, are also important contributors to this difference 114 (5). Because of the small number of genes analyzed in a previous study, we were unable to 115 investigate which biological processes associated with T2D (e.g., insulin production, 116 peripheral insulin resistance, inflammation) were most relevant for the genetic differences 117 between men and women and between early- and late-onset T2D. Given the difference in 118 the degree of association of genes between the two sexes and between the late and early 119 presentation of T2D, it is likely that the biological processes associated with T2D in each 120 group are markedly different.

In this work, a case–control study (n = 2020) was performed, including 69 SNPs associated with T2D located in genes involved in different biological processes. The aim was to solve the following research questions: 1) to confirm whether the influence of genes on T2D is different between men and women, 2) to investigate which biological processes have different weights of contribution in T2D between sexes and age at T2D presentation, and 3) to understand how the contribution of each biological process changes in each group when

127 obesity and parental history of diabetes are included in the MLR models. To identify the 128 factors associated with T2D in each group, univariate logistic regression (ULR) models were used. Then, MLR models were used to calculate the percentage contribution (R²) of each 129 130 factor to the variability of T2D. In the latter, the genes (grouped by biological processes) and 131 the remaining factors were entered in successive blocks to calculate the contribution of each 132 factor (R^2) in the global model. The variation in the order of entry of each factor allowed us to 133 identify how obesity and parental history affect the importance of gene biological processes 134 linked to insulin production and resistance in the variability of T2D between sexes and age of 135 disease onset.

136

137 Material and Methods

138 Sample selection and study design

139 Study participants were part of the Diabetes in Mexico Study (DMS) (21). The DMS study 140 design was previously described as part of the SIGMA Type 2 Diabetes Consortium. Briefly, 141 participants were recruited from two tertiary-level hospitals in Mexico City (Centro Médico 142 Nacional siglo XXI del Seguro Social Mexicano [IMSS], Centro Médico Nacional 20 de 143 Noviembre del Seguro Social para los Trabajadores del Estado [ISSSTE]). T2D was 144 diagnosed according to the criteria of the American Diabetes Association (22). A total of 145 1012 cases (unrelated individuals, >20 years old, with a previous diagnosis of T2D or fasting 146 glucose levels >125 mg/dL) and 1008 controls (healthy subjects, >50 years old, fasting 147 glucose levels <100 mg/dL) were selected from the DMS database, which consisted of 1500 148 controls and 1500 cases of the Latin American mestizo population. Participants and same-149 sex, same-hospital controls were recruited between November 2009 and August 2013. 150 Clinical information including weight, waist and hip circumference, and parental history of 151 T2D was collected during the initial interview. For fasting glucose measurements and DNA 152 extraction, 10 mL of intravenous blood was collected. The association of the 69 selected 153 SNPs, parental history of T2D, BMI, and WHR with T2D was investigated using ULR and 154 MLR models.

This study was approved by the Ethics and Research Committees of the National Institute of Genomic Medicine and the Federal Commission for the Protection against Health Risks (COFEPRIS; approval number CAS/OR/CMN/113300410D0027-0577/2012). The study protocols were carried out in accordance with the ethical principles outlined in the 1964 Declaration of Helsinki. Written informed consent was obtained from all participants prior to their inclusion in the study. This study was not registered in a clinical trial registry.

101

162 SNP selection and genotyping

163 Sixty-nine SNPs were selected; nine associated with T2D in a previous study (5) and 60 164 from different GWAS databases and published articles (Table S1). SNPs with a minor allele 165 frequency (MAF) \geq 10% and OR \geq 1.2 or \leq 0.83 in the Latin American mestizo population and 166 those localized in genes with a role in cellular processes involved in T2D development were 167 prioritized. All DNA samples were genotyped for the 69 SNPs listed in Table S1. Assays 168 were designed using Applied Biosystems TaqMan SNP assay design technology (Foster 169 City, CA, USA). Genotyping was performed by the allelic discrimination assay-by-design 170 TagMan® method on OpenArray® plates. The plates were analyzed on the QuantStudio™ 171 12 K Flex Real-Time PCR System (ThermoFisher Scientific, Waltham, MA, USA). The 172 genotypes were analyzed by Genotyper™ Software v1.3 (ThermoFisher Scientific, Waltham, 173 MA, USA).

174 A total of 23 SNPs that had a difference of distribution between cases and controls of 175 P < 0.2 in the ULR models were ultimately included in the MLR models. The list of SNPs and 176 gene symbols are presented in **Table 1**, and the names of genes and their function in **Table** 177 S2. The SNPs were classified into four groups according to the function and location of the 178 gene in which they occur: Group 1, insulin production located in chromosome region 179 11p15.5 (n = 5); Group 2, insulin production located in other regions (n = 7); Group 3, 180 peripheral insulin resistance (n = 6); and Group 4, inflammation and other functions (n = 5) 181 (Table 1, Table S2).

183 Statistical analyses

When determining the sample size, we considered MLR models to have good performance when there was a baseline of 50 cases (as in the ULR models) and 10–15 additional cases for each variable introduced in the model (23). Given that we planned to introduce 15–20 variables in the MLR models, we calculated a minimum number of 200–350 cases in the comparison groups.

189 Participant age, age at T2D diagnosis, BMI, and WHR were expressed as mean ± 190 standard deviation (SD). Distribution of the frequency of genotypes according to the Hardy-Weinberg law based on the allelic frequency and the formula: $(a + b)^2 = a^2 + 2ab + b^2$, where 191 a and b are the allelic frequencies in the control group, was investigated. Differences in the 192 193 distribution of genotypes between the observed and expected results were calculated using 194 the chi-square test. The BMI was adjusted (BMIadj) for participants who had been diagnosed 195 with T2D for \geq 3 years using data from patients who had been diagnosed with T2D for \leq 2 196 years (5). In the ULR and MLR models, case (diagnosis of T2D) or control was considered a 197 dependent variable; values of the alleles and genotypes of the SNPs, parental history, BMI, 198 and WHR were considered explanatory variables. Interactions between each SNP and both 199 sex and age of T2D presentation were assessed in the ULR models. All variables (BMIadj, 200 WHR, parental history of T2D, and SNPs) were analyzed with stratification by sex (male and 201 female) and age at T2D diagnosis (\leq 45 years and \geq 46 years). The risk conferred by each 202 factor (explanatory variables) was calculated by comparing cases and controls using ULR 203 models. Association was expressed as an OR with 95% confidence intervals (CIs); the contribution to the variability of T2D was expressed as Nagelkerke's R², which represents 204 205 the percentage of T2D variability that can be explained by a named factor (24). Confounders 206 were identified using a theoretical strategy based on a backstep, stepwise MLR model and 207 the change-in-estimate criterion. Variables with P < 0.20 in the ULR analysis were 208 considered for entry in the MLR model. Confounders were defined as those variables for 209 which the percentage difference between the values of the regression β between the

210 adjusted and non-adjusted variables in the stepwise MLR model was larger than 10% (P > 211 0.1). Therefore, the total variability and the contribution of each factor on T2D was calculated 212 using this MLR model. These factors were included successively in the model in different 213 blocks, and the contribution of each factor to the model was assessed by the increase of R² 214 and the decrease in the -2 log likelihood ratio value from one block to the next; the Omnibus 215 test was used to determine whether the differences between the successive blocks were 216 statistically significant. A post-hoc power analysis was performed for each logistic regression 217 model using the software G * Power 3.1.9.2, considering the sample size, the OR, the 218 probability of the event in the control group, and an $\alpha = 0.05$ (25). In addition, for MLR models, the value of the total R^2 obtained at the end of the model was introduced for power 219 220 calculation. 221 All statistical tests were two-sided, and differences were considered significant when 222 P < 0.05. Statistical analyses were conducted using SPSS version 20 software (IBM Corp.,

223 Armonk, NY, USA).

224 **Results**

225 Participant characteristics

The 2020 participants (cases, 1012; controls, 1008) were included in the SNP and BMI
analyses; given missing data for some participants, 1690 were included in the parental
history analysis of T2D and 1335 in the WHR analysis. WHR was not included in some MLR
models; a total of 1690 participants were included in models where parental history was
introduced. The demographic characteristics of patients with T2D and non-diabetic controls
are presented in Table S3.
Among the participants, 53.9% were female and 46.1% were male. The mean ± SD

age of non-diabetic controls (59.1 \pm 11.3 years) was higher than that of cases (55.5 \pm 11.7

years) at the time of enrollment. The mean \pm SD age at T2D diagnosis was 45.8 \pm 10.7

years, and the number of years with T2D varied widely (range, 0-46 years; mean ± SD, 9.5

± 8.7 years). At the time of study recruitment, most patients (89.5%) were taking medication

for their T2D, and few were smokers (cases, 20.2%; controls, 19.8%).

238

239 Identification of genes associated with T2D using ULR models

240 The allelic frequencies of only 23 (Table 1) of the 69 SNPs explored (Table S1) were

significantly different (*P* < 0.1) between cases and controls in all participants (**Table S4**),

stratified by age at T2D diagnosis (≤45 years and ≥46 years) (Table S4), sex (male and

female) (Table S5), or both (Table S6).

In the allelic ULR analysis, 12 of 23 SNPs showed a significant association with T2D for the entire study population (**Table 1**). The R² sum of these 12 SNPs only explains 5.3% of the variability of T2D etiology.

When analyzed according to age of T2D diagnosis (≤45 years versus ≥46 years), 8
of the 12 SNPs associated with T2D in the whole sample were associated with T2D in both

249 age groups (**Table S7**). SNPs in *SLC30A8* (rs3802177), *NOS3* (rs2070744), and *KHDRBS3*

250 (rs6577691) were associated only with early T2D diagnosis and SNPs in CACNA1H

251 (rs4984636) were only associated with late diagnosis. Two additional SNPs, not associated

252 with T2D in the analysis of the entire study population, were also identified: WFS1 253 (rs4458523) (associated with early T2D diagnosis) and HMG20A (rs1005752) (associated 254 with late T2D diagnosis) (Table S7). No major differences were observed in the association 255 of gene groups between early or late T2D diagnosis. However, all SNPs except INS-IGF2 256 (rs149483638) had a greater association with early than late T2D diagnosis. Compared with the overall analysis, the R² sum increased in SNPs associated with early T2D diagnosis (R² 257 sum = 7.37%) and decreased in those associated with late T2D diagnosis (R² sum = 3.32%). 258 259 There was a significant interaction (P < 0.1) between sex and some SNPs, both in 260 the entire study population (n = 8) and when stratified by early (n = 9) and late (n = 6) T2D 261 diagnosis (Table 1, Table S7). Table S5 shows allelic frequency and Table S7 shows the 262 ULR results stratified by sex. Twelve and eight of 23 SNPs were associated with T2D 263 exclusively in males and females, respectively; five were associated with both sexes. A large 264 difference was observed in the association of different groups of genes between males and 265 females. For example, all five SNPs on the chromosome region 11p15.5 were associated 266 with T2D in males but only three SNPs were in females. The two SNPs that were not 267 associated with T2D in females were located at the upstream end of the region where INS 268 and IGF2 are located. Those shared with males, however, were located in the downstream 269 region (KCNQ1 and SLC22A18) (Figure 1). The two SNPs located in KCNQ1 had a stronger association with T2D in males than females (OR >1.6 versus OR = 1.2; P < 0.0001 versus P 270 271 < 0.05), while the SNP in SLC22A18 had a slightly higher association in females versus males (OR >1.43 versus OR = 1.32; P < 0.0002 versus P < 0.007). None of the seven SNPs 272 273 in genes involved with insulin production located in other genomic regions (Group 2) were 274 associated with T2D in females; however, three SNPs (IGF2BP2 [rs4402960], TCF7L2 275 [rs7903146], SLC30A8 [rs3802177]) were associated in males. Peripheral resistance 276 appears more important than insulin production for T2D development in females. The SNP in 277 SLC16A11 had a greater effect in females than males (OR >1.37 versus OR = 1.24; P < 278 0.0004 versus P < 0.021) and the SNP in *PPP1R3A* was only associated with T2D in 279 females.

Overall, ORs were higher and *P* values lower in genes associated with T2D in males versus females. In females, the highest ORs were reported for SNPs in *SLC16A11* (OR, 1.37) and *SLC22A18* (OR, 1.43), while there were five SNPs with an OR > 1.5 (located in *IGF2BP2, INS, KCNQ1*, and *TCF7L2*) for males. The R² sum was 3.5% for females and 10.7% for males. When the analysis was stratified by sex and age of T2D detection some differences in the associations of groups of genes were seen between the two groups of males and females (**Table 2** and see below in the MLR analysis).

287 The observed genotypic frequency was distributed according to the Hardy–Weinberg 288 law in all 23 SNPs studied (Table S8). Genotypic frequency is shown in Table S9 (the total 289 sample stratified by age at T2D diagnosis), Table S10 (stratified by sex), and Table S11 290 (stratified by age at T2D diagnosis and sex). Overall, SNPs associated with T2D in the allelic 291 ULR analysis also showed a significant association in the ULR genotype analysis (Table **S12**). However, in all ULR genotypic models, R² sum values were much higher than those 292 293 observed in the univariate allelic models, clearly indicating that genotypes rather than alleles 294 should be used in MLR models.

295

296 **Degree of participation of each group of genes in the variability of T2D using MLR**

297 *models*

The MLR analyses were performed with the SNP groups (Group 1, Group 2, Group 3, and Group 4) introduced in successive blocks. Most SNPs identified by ULR, except the SNP rs450208 (SLC22A18) in males and SNP rs2237897 (KCNQ1) in females, which could be in partial linkage disequilibrium with some of the other three SNPs located in chromosome region 11p15.5 (**Table S13**), remained in the MLR models (**Table S14**).

The influence of genes on T2D was greatest in males diagnosed early (23.5%), followed by females diagnosed early (13.5%), males diagnosed late (11.9%), and females diagnosed late (7.3%). Genes on the chromosome region 11p15.5 (40.3% of the R²; **Figure 2A**) and others involved in insulin production (35.7% of the R²; **Figure 2A**) had the greatest effect in males diagnosed early, which contrasts with the major influence of genes involved

in peripheral insulin resistance in females diagnosed early (52.3% of the R²; **Figure 2A**).

309 Also notable, males diagnosed late had a predominance of associated SNPs in genes of the

310 chromosome 11p15.5 region, which contrasts with the lower R² values of the same SNPs in

311 females diagnosed late. Although an increase in the influence of genes involved with

inflammation was observed in males and females diagnosed late, it accounted for nearly onequarter of the genes' influence in females.

314

315 Influence of parental history of T2D

316 Parental history had the strongest influence in those cases diagnosed with T2D at ≤45 years 317 of age (males, 19.9%; females, 17.5%) and the least influence in those cases diagnosed 318 with T2D later in life (\leq 6.4%) (**Figure 2B**). History of T2D in both parents had the most 319 influence in both males and females diagnosed early. In contrast, having only a father with 320 T2D had little or no influence on T2D development whereas having a mother with T2D 321 influenced T2D diagnosis, especially among males diagnosed early (25%) and females 322 diagnosed late (50%). The risk of developing T2D early was approximately 10 times higher 323 when both parents and three times higher when one parent had a history of T2D versus 324 neither. In contrast, a history of T2D in both parents conferred a lower risk of T2D in those 325 diagnosed late compared with an early diagnosis (males, 3.6 times higher; females, 2.7 326 times higher versus neither parent with T2D) (data not shown).

In the four groups, the total value of R^2 was higher when parental history was the first 327 block and genes was the second block, particularly for males diagnosed early (R², 0.403) 328 329 (Figure 2C). In this group, gene effects decreased from 0.251 to 0.201 (Figure 2C) as 330 compared with genes in the first block. In contrast, the effect of parental history decreased when analyzing in the opposite order (R^2 decreased from 0.202 to 0.119), suggesting a 331 332 common effect on 5%–8% of T2D variance linked to genes and parental history of T2D, and 333 that much of the effect of parental history is not directly due to the assessed genetic 334 polymorphisms. Interestingly, when the effect of genes is reduced, there is not a uniform 335 reduction for the four groups of genes. Rather, the influence (R²) of genes related to insulin

336 production is decreased (chromosome region 11p15.5 [Group 1], 32%; other genomic 337 regions [Group 2], 34%) and in genes related to peripheral insulin resistance (Group 3), the 338 influence is increased by 25%. In the reverse model (first block, genes; second block, 339 parental history) the decreased influence of parental history was not uniform for a history in 340 the father (decreased from a small effect to no effect), mother (60% decrease), or both (32% 341 decrease) in males diagnosed early (Figure 2C). These data may suggest a relationship 342 between SNPs on genes in the chromosome region 11p15.5 and a maternal history of T2D, 343 especially given that genes in this region have genetic imprinting on the maternal side (26). 344 When stratified by the type of parental inheritance, the distribution of risk alleles compared 345 with alternative alleles for several 11p15.5 genes and TCF7L2 only differs between cases 346 and controls with unilateral maternal inheritance in males diagnosed early (Figure 3).

347

348 Influence of obesity and fat distribution

ULR revealed that BMI was important in all four groups of T2D (males diagnosed early, $R^2 =$ 349 0.198; males diagnosed late, $R^2 = 0.147$; females diagnosed early, $R^2 = 0.132$: females 350 351 diagnosed late. $R^2 = 0.106$) (Figure 4A). WHR was most important for both male groups 352 (Figure 4A). BMI results were similar in MLR models when BMI was the first block (Figure 353 5A and Figure 5B). However, if BMI was the third block (following parental history and 354 genetic influence), the effect decreases substantially (males diagnosed early, 54.6%; males 355 diagnosed late, 34.3%; women diagnosed early, 40.7%; females diagnosed late, 19.9%) 356 (Figure 4B).

Using MLR, the effects of genes and parental history were analyzed separately to determine how much each individually absorbs the effect of BMI (first block, genes or parental history, second block, BMI; first block, BMI, second block, genes or parental history). In males diagnosed early, parental history or genes decreased the effect of BMI by 43.6% or 23.3%, respectively. With parental history as the first block, the effect was mainly absorbed by having a mother with T2D (87.2% increase) or both parents with T2D (72% increase); the effect of a father with T2D was minor (**Figure 5B**). With genes as the first

block, the effect of BMI was mainly absorbed by genes located in the chromosome region
11p15.5 (58.5% increase) (Figure 5A). Similar increases with parental history or genes as
the first block were observed in males diagnosed late and females diagnosed early (Figure
5A and Figure 5B). A similar analysis was performed using WHR rather than BMI. The
findings in males diagnosed early were similar to those found for BMI (Figure 5C and Figure
5D) and together these results suggest that some components of parental history, and to a
lesser extent genes on the chromosome 11p15.5 region, are linked to obesity.

Using the Pearson correlation, we found a positive correlation between the number of risk alleles in *KCNQ1* (chromosome 11p15.5 region) and both BMI and WHR in males diagnosed early (r = 0.125, P = 0.001 and r = 0.130, P < 0.009, respectively) and late (r =0.103, P < 0.007 and r = 0.140, P < 0.003, respectively) (**Figure 6**). A positive correlation was also observed between SNP in *INS* and BMI in males diagnosed early (r = 0.09, P =0.019; data not shown). When BMI was introduced as the last block, the influence of BMI (R^2) was similar

among the four groups of T2D (R^2 range: 0.078–0.094). However, the strength of the BMI effect related to parental history and genes appeared stronger for a late diagnosis compared with an early diagnosis (**Figure 4B**), indicating that obesity is more important than genetic influence and parental history for males and females diagnosed with late-onset T2D.

382 Discussion

383 This study identified notable differences in the association of T2D-related genes, parental 384 history of T2D, BMI, and WHR with T2D development between males and females of Latin 385 American mestizo origin. When participants were stratified by age of T2D presentation, the 386 differences observed between males and females remained regardless of whether they were 387 diagnosed with T2D early (≤45 years) or late (≥46 years). However, in males and females 388 diagnosed late, the influence of genes and family history decreased drastically, while the 389 influence of obesity increased. The reduced effect of T2D-related genes and parental history 390 in late-onset T2D has previously been reported in other studies on White populations (27, 391 28). The three factors (genetic loci, parental history, and BMI) appear related to each other, 392 given that they each compete for a percentage of R^2 (percent of T2D variability explained by 393 each factor). In fact, the relationship of these three factors seems to be much more important 394 in this studied population than in previously analyzed European populations (29). 395 The differences between males and females were most evident in those diagnosed with T2D 396 early: 1) the genetic contribution involved in insulin production was predominant in males 397 while genes involved in peripheral resistance were more important in females, 2) the 398 influence of obesity, especially WHR, was much greater in males than females, and 3) the 399 influence of a mother (unilateral) with a history of T2D greatly influenced males. Given genes 400 that are involved in insulin production are located in autosomes, differences in T2D 401 association should not be related to a differential distribution of risk alleles between males 402 and females. Rather, this is most likely associated with external factors that differentially 403 influence these genes in males and females. Our findings suggest that obesity, hormones, 404 and maternal inheritance may be involved in the selection of males, but not females, who 405 have risk alleles involved in insulin production for the early development of T2D. The 406 association of BMI and especially WHR was much higher in males than females in the group 407 that was diagnosed with T2D early (WHR 16× higher). Also, in males there was a linear 408 correlation between BMI and WHR and the number of risk alleles in several genes located in 409 the chromosome region 11p15.5 (INS and KCNQ1) that are associated with insulin

production. There is clear evidence that sex hormones play an important role in fat
distribution, measured as WHR (30). WHR is a measurement of visceral fat (waist
circumference) and gluteal fat (hip circumference). Gluteal-femoral fat predominates in
females prior to menopause whereas abdominal fat predominates in postmenopausal
females and males of all ages. Abdominal fat has been associated with an increased risk of
developing T2D and cardiovascular disease (31). This may be contributing to the lower risks
of developing T2D in premenopausal females compared with males of the same age (32).

417 The overall prevalence of T2D is slightly higher in males than females (33-35); in the 418 2021 International Diabetes Federation report, the prevalence of T2D in males and females 419 20–79 years of age was 10.8% and 10.2%, respectively (17.7 million more males than 420 females with T2D). However, this difference is not uniform across age ranges; the difference 421 is greatest among those ≤55 years of age (approximately 16.5% versus 13.5%) compared 422 with those who are older, for whom the difference disappears with increasing age (17, 34-423 36). In Mexico, this difference appears even greater. For example, in 2019 the incidence of 424 T2D was 17.2% higher in males than females aged 15–49 years (524 versus 447 425 cases/100,000 persons) (37). This lower prevalence in younger females coincides with the 426 premenopausal period, suggesting a protective effect for estrogens. This protective role has 427 been demonstrated in studies of estradiol (38). Hormone replacement therapy is reported to 428 reduce the incidence of T2D by 35% versus placebo in postmenopausal females (39) and 429 early menopause is associated with an increased risk of T2D (40). Fasting glucose levels in 430 premenopausal females are lower than those in age- and weight-matched males (41), while 431 rat models have shown that estrogens protect against T2D by increasing insulin sensitivity 432 (42, 43) and insulin secretion (43), and decreasing oxidative stress (42). This may suggest 433 that a hormonal effect may protect or delay the impact of genes on the development of T2D 434 in females. Furthermore, overweight or obese males may have low concentrations of serum 435 testosterone, which is associated with an increased risk of T2D (44). A study of males aged 436 50-74 years, with a waist circumference ≥95 cm, serum testosterone concentration ≤14.0 437 nmol/L, and impaired glucose tolerance or newly diagnosed T2D investigated the effects of

participation in a lifestyle program with or without testosterone treatment on T2D (45). The
study found that those who received testosterone treatment for 2 years had a greater
reduction in 2-hour glucose versus baseline than those who received placebo (mean
difference –0.75 mmol/L; p<0.0001). Pancreatic islets have also been shown to be more
susceptible to oxidative stress in males than females (46).

443 It has previously been shown that the influence of maternal history of diabetes is 444 more important than paternal influence, at least for the early development of T2D (47). In the 445 present study, we observed that the parental history of T2D through the mother (unilateral) 446 may play an important role in differences in the association of risk alleles between the sexes 447 in early-diagnosed T2D for two reasons: 1) MLR analysis revealed a substantial reduction in 448 the influence of a mother with T2D when the groups of genes involved in insulin secretion 449 were included in the first block and parental inheritance in the second, and 2) the distribution 450 of risk alleles in INS and KCNQ1 (chromosome 11p15.5 region) and TCF7L2 was 451 significantly different between cases and controls only when the mother had a history of T2D 452 (not with the father or both parents). At least in the case of the chromosome 11p15.5 region, 453 there is evidence of genetic imprinting on the maternal side; a previous study reported that 454 risk alleles in KCNQ1 conferred a risk for T2D only when are inherited by the mother (26) 455 and that risk alleles influenced methylation levels of a regulatory sequence in fetal human 456 pancreas, suggesting that diabetes risk effects may be mediated in early development (48). 457 Interestingly, the effect of maternal inheritance on genes from that region was only observed 458 in males with an early T2D diagnosis. Such an association has not been previously reported. 459 There were also important differences in the T2D models of males and females with 460 a late T2D diagnosis. The effect size of T2D-related genes was larger in males than females, 461 primarily at the expense of the genes involved with insulin production from the chromosome 462 11p15.5 region. It is also noteworthy that in both groups with a late diagnosis, the proportion 463 of the participation of genes involved with inflammation and other processes, relative to the 464 total variance due to genes, was higher than in those with an early diagnosis. This could be 465 related to increased inflammatory processes with aging (49).

466 This study had some limitations. As noted, the number of participants with missing 467 data for WHR was notable. However, the important difference in the median WHR and the 468 degree of association with T2D between men and women, as well as the significant 469 correlation between WHR and the number of risk alleles of the KCNQ1 gene, are very 470 notable. These data could be considered valid because they were explored in ULR analyses. 471 However, it is clear that the interpretation of the effect of WHR in MLR models should be 472 confirmed in studies with a larger sample of cases and controls. Furthermore, this study is 473 also limited by the inclusion of only Mexican participants and therefore the study findings are 474 not necessarily generalizable to other populations. 475 The previous results allow us to conclude that the influence of T2D-related genes,

- 476 maternal T2D history, and fat distribution on T2D development was greater in males than
- 477 females.

478	Funding
-----	---------

- 479 This work was funded by the Fundación Carlos Slim, the Laboratory Huella Génica, and the
- 480 Faculty of Medicine of the Universidad Nacional Autónoma de México (UNAM).

482 Acknowledgements

- 483 The authors thank Sarah Bubeck, PhD, of Edanz (www.edanz.com) for providing medical
- 484 writing support, which was funded by Fundación Carlos Slim, in accordance with Good
- 485 Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).
- 486

487 Data Availability

- 488 All data generated or analyzed during this study are included in this published article and its
- 489 supplementary information files.
- 490

491 Author contributions

- 492 J.B. and R.T.C. made substantial contributions to the conceptualization of the study. J.B.,
- 493 L.O., H.G.R., A.M., and R.T.C. contributed to the study methodology. F.R. utilized software.
- 494 J.B. performed the formal analysis. H.G.O., M.M.M., E.B., E.J.T., A.A.S, L.A.M.J., and
- 495 D.A.A.H. were involved in the study investigation. L.O., R.E.B., and H.G.O. provided
- resources for the study. J.B., H.G.R., L.A.M.J., A.M., D.A.A.H., and R.T.C were involved in
- 497 visualization of the study data. J.B., H.G.R., and R.T.C. supervised the study. R.E.B. was
- 498 involved in project administration and J.B. and R.T.C. acquired funding for the study. J.B.
- 499 wrote the original draft and all authors reviewed and edited the manuscript.

500 References

- Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes
 mellitus and its complications. *Nat Rev Endocrinol.* 2018;14(2):88-98.
- 2. Carey VJ, Walters EE, Colditz GA, Solomon CG, Willett WC, Rosner BA, Speizer FE,
- 504 Manson JE. Body fat distribution and risk of non-insulin-dependent diabetes mellitus
- in women. The Nurses' Health Study. *Am J Epidemiol.* 1997;145(7):614-619.
- 506 3. Hu FB. Obesity epidemiology. Oxford: Oxford University Press; 2008.
- 507 4. Zheng Y, Manson JE, Yuan C, Liang MH, Grodstein F, Stampfer MJ, Willett WC, Hu
- 508 FB. Associations of weight gain from early to middle adulthood with major health 509 outcomes later in life. *JAMA*. 2017;318(3):255-269.
- 5. Berumen J, Orozco L, Betancourt-Cravioto M, Gallardo H, Zulueta M, Mendizabal L,
- 511 Simon L, Benuto RE, Ramírez-Campos E, Marin M, Juárez E, García-Ortiz H,
- 512 Martínez-Hernández A, Venegas-Vega C, Peralta-Romero J, Cruz M, Tapia-Conyer
- R. Influence of obesity, parental history of diabetes, and genes in type 2 diabetes: A
 case-control study. *Sci Rep.* 2019;9(1):2748.
- 515 6. Almgren P, Lehtovirta M, Isomaa B, Sarelin L, Taskinen MR, Lyssenko V, Tuomi T,
- 516 Groop L; Botnia Study Group. Heritability and familiality of type 2 diabetes and
- 517 related quantitative traits in the Botnia Study. *Diabetologia*. 2011;54(11):2811-2819.
- 518 7. Jang HM, Hwang MY, Kim BJ, Kim YJ. Validation and genetic heritability estimation
- of known type 2 diabetes related variants in the Korean population. *Genomics Inform.*2021;19(4):e37.
- 521 8. Chi Y, Wang X, Jia J, Huang T. Smoking status and type 2 diabetes, and
- 522 cardiovascular dsease: A comprehensive analysis of shared genetic etiology and
 523 causal relationship. *Front Endocrinol (Lausanne)*. 2022;13:809445.
- 524 9. Fuchsberger C, Flannick J, Teslovich TM, Mahajan A, Agarwala V, Gaulton KJ, Ma
- 525 C, Fontanillas P, Moutsianas L, McCarthy DJ, Rivas MA, Perry JRB, Sim X,
- 526 Blackwell TW, Robertson NR, Rayner NW, Cingolani P, Locke AE, Tajes JF,
- 527 Highland HM, Dupuis J, Chines PS, Lindgren CM, Hartl C, Jackson AU, Chen H,

528 Huyghe JR, van de Bunt M, Pearson RD, Kumar A, Müller-Nurasvid M, Grarup N, 529 Stringham HM, Gamazon ER, Lee J, Chen Y, Scott RA, Below JE, Chen P, Huang J, 530 Go MJ, Stitzel ML, Pasko D, Parker SCJ, Varga TV, Green T, Beer NL, Day-Williams 531 AG, Ferreira T, Fingerlin T, Horikoshi M, Hu C, Huh I, Ikram MK, Kim BJ, Kim Y, Kim 532 YJ, Kwon MS, Lee J, Lee S, Lin KH, Maxwell TJ, Nagai Y, Wang X, Welch RP, Yoon 533 J, Zhang W, Barzilai N, Voight BF, Han BG, Jenkinson CP, Kuulasmaa T, Kuusisto J, 534 Manning A, Ng MCY, Palmer ND, Balkau B, Stančáková A, Abboud HE, Boeing H, 535 Giedraitis V, Prabhakaran D, Gottesman O, Scott J, Carey J, Kwan P, Grant G, 536 Smith JD, Neale BM, Purcell S, Butterworth AS, Howson JMM, Lee HM, Lu Y, Kwak 537 SH, Zhao W, Danesh J, Lam VKL, Park KS, Saleheen D, So WY, Tam CHT, Afzal U, 538 Aguilar D, Arya R, Aung T, Chan E, Navarro C, Cheng CY, Palli D, Correa A, Curran JE, Rybin D, Farook VS, Fowler SP, Freedman BI, Griswold M, Hale DE, Hicks PJ, 539 540 Khor CC, Kumar S, Lehne B, Thuillier D, Lim WY, Liu J, van der Schouw YT, Loh M, Musani SK, Puppala S, Scott WR, Yengo L, Tan ST, Taylor HA Jr, Thameem F, 541 Wilson G Sr, Wong TY, Njølstad PR, Levy JC, Mangino M, Bonnycastle LL, 542 543 Schwarzmayr T, Fadista J, Surdulescu GL, Herder C, Groves CJ, Wieland T, Bork-Jensen J, Brandslund I, Christensen C, Koistinen HA, Doney ASF, Kinnunen L, Esko 544 T, Farmer AJ, Hakaste L, Hodgkiss D, Kravic J, Lyssenko V, Hollensted M, 545 546 Jørgensen ME, Jørgensen T, Ladenvall C, Justesen JM, Käräjämäki A, Kriebel J, Rathmann W, Lannfelt L, Lauritzen T, Narisu N, Linneberg A, Melander O, Milani L, 547 548 Neville M, Orho-Melander M, Qi L, Qi Q, Roden M, Rolandsson O, Swift A, 549 Rosengren AH, Stirrups K, Wood AR, Mihailov E, Blancher C, Carneiro MO, Maguire 550 J, Poplin R, Shakir K, Fennell T, DePristo M, de Angelis MH, Deloukas P, Gjesing 551 AP, Jun G, Nilsson P, Murphy J, Onofrio R, Thorand B, Hansen T, Meisinger C, Hu 552 FB, Isomaa B, Karpe F, Liang L, Peters A, Huth C, O'Rahilly SP, Palmer CNA, 553 Pedersen O, Rauramaa R, Tuomilehto J, Salomaa V, Watanabe RM, Syvänen AC, 554 Bergman RN, Bharadwaj D, Bottinger EP, Cho YS, Chandak GR, Chan JCN, Chia 555 KS, Daly MJ, Ebrahim SB, Langenberg C, Elliott P, Jablonski KA, Lehman DM, Jia

556		W, Ma RCW, Pollin TI, Sandhu M, Tandon N, Froguel P, Barroso I, Teo YY, Zeggini
557		E, Loos RJF, Small KS, Ried JS, DeFronzo RA, Grallert H, Glaser B, Metspalu A,
558		Wareham NJ, Walker M, Banks E, Gieger C, Ingelsson E, Im HK, Illig T, Franks PW,
559		Buck G, Trakalo J, Buck D, Prokopenko I, Mägi R, Lind L, Farjoun Y, Owen KR,
560		Gloyn AL, Strauch K, Tuomi T, Kooner JS, Lee JY, Park T, Donnelly P, Morris AD,
561		Hattersley AT, Bowden DW, Collins FS, Atzmon G, Chambers JC, Spector TD,
562		Laakso M, Strom TM, Bell GI, Blangero J, Duggirala R, Tai ES, McVean G, Hanis
563		CL, Wilson JG, Seielstad M, Frayling TM, Meigs JB, Cox NJ, Sladek R, Lander ES,
564		Gabriel S, Burtt NP, Mohlke KL, Meitinger T, Groop L, Abecasis G, Florez JC, Scott
565		LJ, Morris AP, Kang HM, Boehnke M, Altshuler D, McCarthy MI. The genetic
566		architecture of type 2 diabetes. Nature. 2016;536(7614):41-47.
567	10.	Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI,
568		Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L,
569		Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG,
570		Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM. Finding
571		the missing heritability of complex diseases. Nature. 2009;461(7265):747-753.
572	11.	Wang L, Lee S, Gim J, Qiao D, Cho M, Elston RC, Silverman EK, Won S. Family-
573		based rare variant association analysis: A fast and efficient method of multivariate
574		phenotype association analysis. Genet Epidemiol. 2016;40(6):502-511.
575	12.	Ma Y, Zhou Z, Li X, Yan Z, Ding K, Xiao H, Wu Y, Wu T, Chen D. Integrative
576		identification of genetic loci jointly influencing diabetes-related traits and sleep traits
577		of insomnia, sleep duration, and chronotypes. Biomedicines. 2022;10(2):368.
578	13.	Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, Payne AJ,
579		Steinthorsdottir V, Scott RA, Grarup N, Cook JP, Schmidt EM, Wuttke M, Sarnowski
580		C, Mägi R, Nano J, Gieger C, Trompet S, Lecoeur C, Preuss MH, Prins BP, Guo X,
581		Bielak LF, Below JE, Bowden DW, Chambers JC, Kim YJ, Ng MCY, Petty LE, Sim X,
582		Zhang W, Bennett AJ, Bork-Jensen J, Brummett CM, Canouil M, Ec Kardt KU,
583		Fischer K, Kardia SLR, Kronenberg F, Läll K, Liu CT, Locke AE, Luan J, Ntalla I,

584		Nylander V, Schönherr S, Schurmann C, Yengo L, Bottinger EP, Brandslund I,
585		Christensen C, Dedoussis G, Florez JC, Ford I, Franco OH, Frayling TM, Giedraitis
586		V, Hackinger S, Hattersley AT, Herder C, Ikram MA, Ingelsson M, Jørgensen ME,
587		Jørgensen T, Kriebel J, Kuusisto J, Ligthart S, Lindgren CM, Linneberg A, Lyssenko
588		V, Mamakou V, Meitinger T, Mohlke KL, Morris AD, Nadkarni G, Pankow JS, Peters
589		A, Sattar N, Stančáková A, Strauch K, Taylor KD, Thorand B, Thorleifsson G,
590		Thorsteinsdottir U, Tuomilehto J, Witte DR, Dupuis J, Peyser PA, Zeggini E, Loos
591		RJF, Froguel P, Ingelsson E, Lind L, Groop L, Laakso M, Collins FS, Jukema JW,
592		Palmer CNA, Grallert H, Metspalu A, Dehghan A, Köttgen A, Abecasis GR, Meigs
593		JB, Rotter JI, Marchini J, Pedersen O, Hansen T, Langenberg C, Wareham NJ,
594		Stefansson K, Gloyn AL, Morris AP, Boehnke M, McCarthy MI. Fine-mapping type 2
595		diabetes loci to single-variant resolution using high-density imputation and islet-
596		specific epigenome maps. Nat Genet. 2018;50(11):1505-1513.
597	14.	Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M,
598		Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, Johansen CT, Fouchier SW, Isaacs
599		A, Peloso GM, Barbalic M, Ricketts SL, Bis JC, Aulchenko YS, Thorleifsson G,
600		Feitosa MF, Chambers J, Orho-Melander M, Melander O, Johnson T, Li X, Guo X, Li
601		M, Shin Cho Y, Jin Go M, Jin Kim Y, Lee JY, Park T, Kim K, Sim X, Twee-Hee Ong
602		R, Croteau-Chonka DC, Lange LA, Smith JD, Song K, Hua Zhao J, Yuan X, Luan J,
603		Lamina C, Ziegler A, Zhang W, Zee RY, Wright AF, Witteman JC, Wilson JF,
604		Willemsen G, Wichmann HE, Whitfield JB, Waterworth DM, Wareham NJ, Waeber G,
605		Vollenweider P, Voight BF, Vitart V, Uitterlinden AG, Uda M, Tuomilehto J,
606		Thompson JR, Tanaka T, Surakka I, Stringham HM, Spector TD, Soranzo N, Smit
607		JH, Sinisalo J, Silander K, Sijbrands EJ, Scuteri A, Scott J, Schlessinger D, Sanna S,
608		Salomaa V, Saharinen J, Sabatti C, Ruokonen A, Rudan I, Rose LM, Roberts R,
609		Rieder M, Psaty BM, Pramstaller PP, Pichler I, Perola M, Penninx BW, Pedersen NL,
610		Pattaro C, Parker AN, Pare G, Oostra BA, O'Donnell CJ, Nieminen MS, Nickerson
611		DA, Montgomery GW, Meitinger T, McPherson R, McCarthy MI, McArdle W, Masson

612		D, Martin NG, Marroni F, Mangino M, Magnusson PK, Lucas G, Luben R, Loos RJ,
613		Lokki ML, Lettre G, Langenberg C, Launer LJ, Lakatta EG, Laaksonen R, Kyvik KO,
614		Kronenberg F, König IR, Khaw KT, Kaprio J, Kaplan LM, Johansson A, Jarvelin MR,
615		Janssens AC, Ingelsson E, Igl W, Kees Hovingh G, Hottenga JJ, Hofman A, Hicks
616		AA, Hengstenberg C, Heid IM, Hayward C, Havulinna AS, Hastie ND, Harris TB,
617		Haritunians T, Hall AS, Gyllensten U, Guiducci C, Groop LC, Gonzalez E, Gieger C,
618		Freimer NB, Ferrucci L, Erdmann J, Elliott P, Ejebe KG, Döring A, Dominiczak AF,
619		Demissie S, Deloukas P, de Geus EJ, de Faire U, Crawford G, Collins FS, Chen YD,
620		Caulfield MJ, Campbell H, Burtt NP, Bonnycastle LL, Boomsma DI, Boekholdt SM,
621		Bergman RN, Barroso I, Bandinelli S, Ballantyne CM, Assimes TL, Quertermous T,
622		Altshuler D, Seielstad M, Wong TY, Tai ES, Feranil AB, Kuzawa CW, Adair LS,
623		Taylor HA Jr, Borecki IB, Gabriel SB, Wilson JG, Holm H, Thorsteinsdottir U,
624		Gudnason V, Krauss RM, Mohlke KL, Ordovas JM, Munroe PB, Kooner JS, Tall AR,
625		Hegele RA, Kastelein JJ, Schadt EE, Rotter JI, Boerwinkle E, Strachan DP, Mooser
626		V, Stefansson K, Reilly MP, Samani NJ, Schunkert H, Cupples LA, Sandhu MS,
627		Ridker PM, Rader DJ, van Duijn CM, Peltonen L, Abecasis GR, Boehnke M,
628		Kathiresan S. Biological, clinical and population relevance of 95 loci for blood lipids.
629		Nature. 2010;466(7307):707-713.
630	15.	Piko P, Werissa NA, Fiatal S, Sandor J, Adany R. Impact of genetic factors on the
631		age of onset for type 2 diabetes mellitus in addition to the conventional risk factors. J
632		Pers Med. 2020;11(1):6.
633	16.	Humphries SE, Gable D, Cooper JA, Ireland H, Stephens JW, Hurel SJ, Li KW,
634		Palmen J, Miller MA, Cappuccio FP, Elkeles R, Godsland I, Miller GJ, Talmud PJ.
635		Common variants in the TCF7L2 gene and predisposition to type 2 diabetes in UK
636		European Whites, Indian Asians and Afro-Caribbean men and women. J Mol Med
637		(Berl). 2006;84(12)1005-1014.

638	17.	Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk,
639		pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev.
640		2016;37(3):278-316.
641	18.	SIGMA Type 2 Diabetes Consortium, Williams AL, Jacobs SB, Moreno-Macías H,
642		Huerta-Chagoya A, Churchhouse C, Márquez-Luna C, García-Ortíz H, Gómez-
643		Vázquez MJ, Burtt NP, Aguilar-Salinas CA, González-Villalpando C, Florez JC,
644		Orozco L, Haiman CA, Tusié-Luna T, Altshuler D. Sequence variants in SLC16A11
645		are a common risk factor for type 2 diabetes in Mexico. Nature. 2014;506(7486)97-
646		101.
647	19.	Mercader JM, Florez JC. The genetic basis of type 2 diabetes in Hispanics and Latin
648		Americans: Challenges and opportunities. Front Public Health. 2017;5:329.
649	20.	SIGMA Type 2 Diabetes Consortium, Estrada K, Aukrust I, Bjørkhaug L, Burtt NP,
650		Mercader JM, García-Ortiz H, Huerta-Chagoya A, Moreno-Macías H, Walford G,
651		Flannick J, Williams AL, Gómez-Vázquez MJ, Fernandez-Lopez JC, Martínez-
652		Hernández A, Jiménez-Morales S, Centeno-Cruz F, Mendoza-Caamal E, Revilla-
653		Monsalve C, Islas-Andrade S, Córdova EJ, Soberón X, González-Villalpando ME,
654		Henderson E, Wilkens LR, Le Marchand L, Arellano-Campos O, Ordóñez-Sánchez
655		ML, Rodríguez-Torres M, Rodríguez-Guillén R, Riba L, Najmi LA, Jacobs SB, Fennell
656		T, Gabriel S, Fontanillas P, Hanis CL, Lehman DM, Jenkinson CP, Abboud HE, Bell
657		GI, Cortes ML, Boehnke M, González-Villalpando C, Orozco L, Haiman CA, Tusié-
658		Luna T, Aguilar-Salinas CA, Altshuler D, Njølstad PR, Florez JC, MacArthur DG.
659		Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino
660		population. JAMA. 2014;311(22):2305-2314.
661	21.	Mercader JM, Liao RG, Bell AD, Dymek Z, Estrada K, Tukiainen T, Huerta-Chagoya
662		A, Moreno-Macías H, Jablonski KA, Hanson RL, Walford GA, Moran I, Chen L,
663		Agarwala V, Ordoñez-Sánchez ML, Rodríguez-Guillen R, Rodríguez-Torres M,
664		Segura-Kato Y, García-Ortiz H, Centeno-Cruz F, Barajas-Olmos F, Caulkins L,
665		Puppala S, Fontanillas P, Williams AL, Bonàs-Guarch S, Hartl C, Ripke S; Diabetes

666		Prevention Program Research Group, Tooley K, Lane J, Zerrweck C, Martínez-
667		Hernández A, Córdova EJ, Mendoza-Caamal E, Contreras-Cubas C, González-
668		Villalpando ME, Cruz-Bautista I, Muñoz-Hernández L, Gómez-Velasco D, Alvirde U,
669		Henderson BE, Wilkens LR, Le Marchand L, Arellano-Campos O, Riba L, Harden M;
670		Broad Genomics Platform, Gabriel S; T2D-GENES Consortium, Abboud HE, Cortes
671		ML, Revilla-Monsalve C, Islas-Andrade S, Soberon X, Curran JE, Jenkinson CP,
672		DeFronzo RA, Lehman DM, Hanis CL, Bell GI, Boehnke M, Blangero J, Duggirala R,
673		Saxena R, MacArthur D, Ferrer J, McCarroll SA, Torrents D, Knowler WC, Baier LJ,
674		Burtt N, González-Villalpando C, Haiman CA, Aguilar-Salinas CA, Tusié-Luna T,
675		Flannick J, Jacobs SBR, Orozco L, Altshuler D, Florez JC; SIGMA T2D Genetics
676		Consortium. A loss-of-function splice acceptor variant in IGF2 is protective for type 2
677		diabetes. Diabetes. 2017;66(11): 2903-2914.
678	22.	American Diabetes Association. Standards of Medical Care in Diabetes-2022
679		Abridged for Primary Care Providers. Clin Diabetes. 2022;40(1):10-38.
680	23.	Babyak MA. What you see may not be what you get: a brief, nontechnical
681		introduction to overfitting in regression-type models. Psychosom Med.
682		2004;66(3):411-421.
683	24.	Nagelkerke NJD. A note on a general definition of the coefficient of determination.
684		Biometrika. 1991;78(3):691-692.
685	25.	Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power
686		analysis program for the social, behavioral, and biomedical sciences. Behav Res
687		Methods. 2007;39(2):175-191.
688	26.	Kong A, Steinthorsdottir V, Masson G, Thorleifsson G, Sulem P, Besenbacher S,
689		Jonasdottir A, Sigurdsson A, Kristinsson KT, Jonasdottir A, Frigge ML, Gylfason A,
690		Olason PI, Gudjonsson SA, Sverrisson S, Stacey SN, Sigurgeirsson B,
691		Benediktsdottir KR, Sigurdsson H, Jonsson T, Benediktsson R, Olafsson JH,
692		Johannsson OT, Hreidarsson AB, Sigurdsson G; DIAGRAM Consortium, Ferguson-
693		Smith AC, Gudbjartsson DF, Thorsteinsdottir U, Stefansson K. Parental origin of

sequence variants associated with complex diseases. *Nature*. 2009;462(7275):868874.

696 27. Ding M, Ahmad S, Qi L, Hu Y, Bhupathiraju SN, Guasch-Ferré M, Jensen MK, 697 Chavarro JE, Ridker PM, Willett WC, Chasman DI, Hu FB, Kraft P. Additive and 698 multiplicative interactions between genetic risk score and family history and lifestyle 699 in relation to risk of type 2 diabetes. Am J Epidemiol. 2020;189(5):445-460. 700 28. Amuta AO, Mkuu R, Jacobs W, Barry AE. Number and severity of type 2 diabetes 701 among family members are associated with nutrition and physical activity behaviors. 702 Front Public Health. 2017;5:157. 703 29. InterAct Consortium, Scott RA, Langenberg C, Sharp SJ, Franks PW, Rolandsson O, 704 Drogan D, van der Schouw YT, Ekelund U, Kerrison ND, Ardanaz E, Arriola L, 705 Balkau B, Barricarte A, Barroso I, Bendinelli B, Beulens JW, Boeing H, de Lauzon-706 Guillain B, Deloukas P, Fagherazzi G, Gonzalez C, Griffin SJ, Groop LC, Halkjaer J, 707 Huerta JM, Kaaks R, Khaw KT, Krogh V, Nilsson PM, Norat T, Overvad K, Panico S, 708 Rodriguez-Suarez L, Romaguera D, Romieu I, Sacerdote C, Sánchez MJ, 709 Spijkerman AM, Teucher B, Tjonneland A, Tumino R, van der A DL, Wark PA, 710 McCarthy MI, Riboli E, Wareham NJ. The link between family history and risk of type 711 2 diabetes is not explained by anthropometric, lifestyle or genetic risk factors: the 712 EPIC-InterAct study. Diabetologia. 2013;56(1):60-69. 713 Watts EL, Appleby PN, Albanes D, Black A, Chan JM, Chen C, Cirillo PM, Cohn BA, 30. 714 Cook MB, Donovan JL, Ferrucci L, Garland CF, Giles GG, Goodman PJ, Habel LA, Haiman CA, Holly JMP, Hoover RN, Kaaks R, Knekt P, Kolonel LN, Kubo T, Le 715 716 Marchand L, Luostarinen T, MacInnis RJ, Mäenpää HO, Männistö S, Metter EJ, 717 Milne RL, Nomura AMY, Oliver SE, Parsons JK, Peeters PH, Platz EA, Riboli E, 718 Ricceri F, Rinaldi S, Rissanen H, Sawada N, Schaefer CA, Schenk JM, Stanczyk FZ, 719 Stampfer M, Stattin P, Stenman UH, Tjønneland A, Trichopoulou A, Thompson IM, 720 Tsugane S, Vatten L, Whittemore AS, Ziegler RG, Allen NE, Key TJ, Travis RC. 721 Circulating sex hormones in relation to anthropometric, sociodemographic and

722		behavioural factors in an international dataset of 12,300 men. PLoS One.
723		2017;12(12): e0187741.
724	31.	Benz V, Kintscher U, Foryst-Ludwig A. Sex-specific differences in Type 2 Diabetes
725		Mellitus and dyslipidemia therapy: PPAR agonists. Handb Exp Pharmacol.
726		2012;(214):387-410.
727	32.	Zhang H, Sairam, MR. Sex hormone imbalances and adipose tissue dysfunction
728		impacting on metabolic syndrome; a paradigm for the discovery of novel adipokines.
729		Horm Mol Biol Clin Investig. 2014;17(2):89-97.
730	33.	Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes:
731		estimates for the year 2000 and projections for 2030. Diabetes Care.
732		2004;27(5):1047-1053.
733	34.	Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology
734		of type 2 diabetes - Global burden of disease and forecasted trends. J Epidemiol
735		Glob Health. 2020;10(1):107-111.
736	35.	International Diabetes Federation. IDF Diabetes Atlas 2021: IDF Atlas. 10th Edition.
737		Available from: https://diabetesatlas.org/atlas/tenth-edition/.
738	36.	Wändell PE, Carlsson AC. Gender differences and time trends in incidence and
739		prevalence of type 2 diabetes in Swedena model explaining the diabetes epidemic
740		worldwide today? Diabetes Res Clin Pract. 2014;106(3):e90-92.
741	37.	Institute for Health Metrics and Evaluation. GBD 2019. Available from:
742		http://ihmeuw.org/5pb2.
743	38.	Fappi A, Mittendorfer B. Different physiological mechanisms underlie an adverse
744		cardiovascular disease risk profile in men and women. Proc Nutr Soc.
745		2020;79(2):210-218.
746	39.	Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, Cauley JA,
747		Barrett-Connor E; Heart and Estrogen/progestin Replacement Study. Glycemic
748		effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin

749 Replacement Study. A randomized, double-blind, placebo-controlled trial. *Ann Intern*750 *Med.* 2003;138(1):1-9.

751	40.	Brand JS, van der Schouw YT, Onland-Moret NC, Sharp SJ, Ong KK, Khaw KT,
752		Ardanaz E, Amiano P, Boeing H, Chirlaque MD, Clavel-Chapelon F, Crowe FL, de
753		Lauzon-Guillain B, Duell EJ, Fagherazzi G, Franks PW, Grioni S, Groop LC, Kaaks
754		R, Key TJ, Nilsson PM, Overvad K, Palli D, Panico S, Quirós JR, Rolandsson O,
755		Sacerdote C, Sánchez MJ, Slimani N, Teucher B, Tjonneland A, Tumino R, van der
756		A DL, Feskens EJ, Langenberg C, Forouhi NG, Riboli E, Wareham NJ; InterAct
757		Consortium. Age at menopause, reproductive life span, and type 2 diabetes risk:
758		results from the EPIC-InterAct study. Diabetes Care. 2013;36(4):1012-1019.
759	41.	Anderwald C, Gastaldelli A, Tura A, Krebs M, Promintzer-Schifferl M, Kautzky-Willer
760		A, Stadler M, DeFronzo RA, Pacini G, Bischof MG. Mechanism and effects of
761		glucose absorption during an oral glucose tolerance test among females and males.
762		J Clin Endocrinol Metab. 2011;96(2):515-524.
763	42.	Díaz A, López-Grueso R, Gambini J, Monleón D, Mas-Bargues C, Abdelaziz KM,
764		Viña J, Borrás C. Sex differences in age-associated type 2 diabetes in rats-Role of
765		estrogens and oxidative stress. Oxid Med Cell Longev. 2019;2019: 6734836.
766	43.	Bian C, Bai B, Gao Q, Li S, Zhao Y. 17beta-estradiol regulates glucose metabolism
767		and insulin secretion in rat islet beta cells through GPER and Akt/mTOR/GLUT2
768		pathway. Front Endocrinol (Lausanne). 2019;10:531.
769	44.	Fui MN, Dupuis P, Grossmann M. Lowered testosterone in male obesity:
770		mechanisms, morbidity and management. Asian J Androl. 2014;16(2):223-231.
771	45.	Wittert G, Bracken K, Robledo KP, Grossmann M, Yeap BB, Handelsman DJ,
772		Stuckey B, Conway A, Inder W, McLachlan R, Allan C, Jesudason D, Fui MNT,
773		Hague W, Jenkins A, Daniel M, Gebski V, Keech A. Testosterone treatment to
774		prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a
775		randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes
776		Endocrinol. 2021;9(1):32-45.

777	46.	Yokomizo H, Inoguchi T, Sonoda N, Sakaki Y, Maeda Y, Inoue T, Hirata E, Takei R,
778		Ikeda N, Fujii M, Fukuda K, Sasaki H, Takayanagi R. Maternal high-fat diet induces
779		insulin resistance and deterioration of pancreatic beta-cell function in adult offspring
780		with sex differences in mice. Am J Physiol Endocrinol Metab. 2014;306(10):E1163-
781		1175.
782	47.	Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes: the
783		Framingham Offspring Study. Diabetes. 2000;49(12):2201-2207.
784	48.	Travers ME, Mackay DJ, Dekker Nitert M, Morris AP, Lindgren CM, Berry A, Johnson
785		PR, Hanley N, Groop LC, McCarthy MI, Gloyn AL. Insights into the molecular
786		mechanism for type 2 diabetes susceptibility at the KCNQ1 locus from temporal
787		changes in imprinting status in human islets. Diabetes. 2013;62(3):987-992.
788	49.	Thakur N, Tiwari VK, Thomassin H, Pandey RR, Kanduri M, Göndör A, Grange T,
789		Ohlsson R, Kanduri C. An antisense RNA regulates the bidirectional silencing
790		property of the Kcnq1 imprinting control region. Mol Cell Biol. 2004;24(18):7855-
791		7862.

792 Figure legends

- **Figure 1.** Graphic representation of the chromosome 11p15.5 region.
- 794
- **Figure 2.** Influence (R^2) of genes and parental history of T2D on T2D development.
- 796 MLR analysis stratified by age at T2D diagnosis and sex was conducted to demonstrate (A)
- the effect of groups of genes, (B) parental history, and (C) both factors on T2D development
- 798 (early diagnosis was ≤45 years whereas late diagnosis was ≥46 years). Gene groups and
- 799 parental history as factors were introduced into the models as successive blocks. The gene
- groups were as follows: Group 1, five SNPs located in genes on chromosome region
- 11p15.5 that are in involved in insulin production (*INS*, *IGF*2, and *KCNQ1*); Group 2, seven
- 802 SNPs located in genes outside of chromosome 11 and involved in insulin production; Group
- 3, six SNPs located in genes involved in peripheral insulin resistance; Group 4, five SNPs
- 804 located in genes involved in inflammation and other functions. The influence of parental
- history of T2D was investigated according to having a mother with T2D, a father with T2D, or
- 806 both parents with T2D. In panel C, the effects of genes and parental history were
- investigated with genes as the first block and parental history as the second block and viceversa.
- Abbreviations: MLR, multivariate logistic regression; SNP, single nucleotide polymorphism;
 T2D, type 2 diabetes.
- 811

Figure 3. Analysis of allelic frequency stratified by type of parental history of T2D in males
diagnosed early. A comparison of frequencies of risk and alternative alleles for SNPs in
genes located in the chromosome region 11p15.5 (*INS* and *KCNQ1*) and *TCF7L2* between
cases and controls stratified by the type of parental history of T2D (mother only, father only,
both parents). *P* values were calculated using a chi-square test.
Abbreviations: SNP, single nuclear polymorphism; T2D, type 2 diabetes.

818

Figure 4. Influence (R²) of genes, parental history of T2D, BMI, and WHR on T2D
development. (A) MLR analysis was conducted to determine the involvement of BMI and
WHR in the four models of T2D (stratified by age of T2D diagnosis and sex). (B) MLR
analysis of the participation of parental history, genes, and adjusted BMI in the four models.
Abbreviations: BMI, body mass index; MLR, multivariate logistic regression; T2D, type 2
diabetes; WHR, waist-hip ratio.

825

Figure 5. Influence (\mathbb{R}^2) of obesity and fat distribution and genes and parental history on T2D development overlap. Overlapping analysis was performed with stratification by age of T2D diagnosis and sex. Overlapping analysis of (A) BMI with genes, (B) BMI with parental history, (C) WHR with genes, and (D) WHR with parental history are shown. The overlapping effect of \mathbb{R}^2 between genes and BMI and between parental history and BMI was observed by introducing BMI as the first block and either genes or parental history as the second block and then conducting the analysis with the blocks reversed.

Abbreviations: BMI, body mass index; PH, parental history; T2D, type 2 diabetes; WHR,
weight distribution.

835

Figure 6. Correlation analysis between the number of risk alleles in *KCNQ1* in relation to

obesity and fat distribution. (A) Correlation between the number of risk alleles in KCNQ1 and

BMI in males and females with a T2D diagnosis \leq 45 years and \geq 46 years of age. (B)

839 Correlation between the number of risk alleles in *KCNQ1* and WHR in males and females

840 with a T2D diagnosis \leq 45 years and \geq 46 years of age. Correlations and *P* values were

calculated using the Pearson correlation test.

Abbreviations: BMI, body mass index; T2D, type 2 diabetes; WHR, weight distribution.

843 Tables

Table 1. Association of 23 SNPs with type 2 diabetes among the whole sample (N = 4040 chromosomes)

Locus (SNP)	Chr	Position	RA	AA	MAF	ULR				
						OR (95% CI)	p-Wald	R ²	SI	
Group 1										
INS-IGF2 (rs149483638)	11	2140300	С	T ^a	0.281	1.25 (1.1–1.4)	0.0022	0.003	>0.05	
INS (rs689)	11	2160994	A ^a	т	0.188	1.32 (1.1–1.5)	0.0005	0.004	0.06	
KCNQ1 (rs2237897)	11	2837316	С	T ^a	0.392	1.44 (1.3–1.6)	< 0.0001	0.010	>0.05	
KCNQ1 (rs163168)	11	2803115	С	T ^a	0.436	1.39 (1.2–1.6)	< 0.0001	0.008	>0.05	
SLC22A18 (rs450208)	11	2910751	Т	G^{a}	0.311	1.38 (1.2–1.6)	< 0.0001	0.007	>0.05	
Group 2										
IGF2BP2 (rs4402960)	3	185793899	T ^a	G	0.163	1.28 (1.1–1.5)	0.0031	0.003	0.07	
TCF7L2 (rs7903146)	10	112998590	T ^a	С	0.121	1.5 (1.3–1.8)	< 0.0001	0.007	>0.05	
CDKN2A (rs10811661)	9	22134095	Т	C^{a}	0.096	1.12 (0.9–1.4)	0.029	0	>0.05	
SLC30A8 (rs3802177)	8	117172786	A ^a	G	0.272	1.15 (1–1.3)	0.044	0.001	>0.05	
HNF1A (rs483353044)	12	120999288	A ^a	G	0.003	2 (0.8–5)	0.13	0.001	>0.05	
WFS1 (rs4458523)	4	6288259	G	T ^a	0.233	1.07 (0.9–1.2)	0.35	0	>0.05	
HMG20A (rs1005752)	15	77525786	C ^a	А	0.419	0.94 (0.8–1.1)	0.34	0	>0.05	

Group 3

SLC16A11 (rs75493593)	17	7041768	T ^a	G	0.374	1.31 (1.2–1.5)	<0.0001	0.006	>0.05
IRS1 (rs1801278)	2	226795828	T^{a}	С	0.027	0.98 (0.7–1.4)	0.91	0	>0.05
FABP2 (rs1799883)	4	119320747	T ^a	С	0.241	0.99 (0.9–1.1)	0.89	0	>0.05
CAPN10 (rs7607759)	2	240596709	Gª	А	0.053	1.04 (0.8–1.4)	0.76	0	>0.05
PPP1R3A (rs1799999)	7	113878379	A ^a	С	0.291	1.09 (0.9–1.2)	0.23	0	>0.05
PTPRD (rs10511567)	9	11606348	C^{a}	Т	0.278	1.02 (0.9–1.2)	0.76	0	>0.05
Group 4									
IL6 (rs1800795)	7	22727026	C^{a}	G	0.079	1.01 (0.8–1.3)	0.93	0	>0.05
NOS3 (rs2070744)	7	150992991	C^{a}	Т	0.145	0.84 (0.7–1)	0.054	0.001	>0.05
CPED1 (rs10261386)	7	120711855	C^{a}	Т	0.347	1.04 (0.9–1.2)	0.55	0	>0.05
KHDRBS3 (rs6577691)	8	135961229	G^{a}	Т	0.123	0.84 (0.7–1)	0.076	0.001	>0.05
CACNA1H (rs4984636)	16	1202441	C^{a}	Т	0.113	0.83 (0.7–1)	0.073	0.001	>0.05
No. genes							12		
Sum of univariate R ²							0.053		

Abbreviations: AA, alternative allele; Chr, chromosome; CI, confidence interval; MAF, major allele frequency; OR, odds ratio; R²,

variability of T2D explained by the SNP; RA, risk allele; SI, sex interaction; SNP, single nucleotide polymorphism; ULR, univariate

847 logistic regression.

^aMinor allele.

- 849 Group 1, insulin production located in the chromosome region 11p15.5; Group 2, insulin production located in other chromosomes;
- Group 3, peripheral insulin resistance; Group 4, inflammation and other functions

Table 2. Allele association of 23 SNPs with type 2 diabetes stratified by age of type 2 diabetes diagnosis and sex among the

	ULR							
Locus (SNP)	T2D diagnosis ≤45 years				T2D diagnosis ≥46 years			
	Females		Males		Females		Males	
	OR (95% CI)	p-Wald	OR (95% CI)	p-Wald	OR (95% CI)	p-Wald	OR (95% CI)	p-Wald
Group 1								
INS-IGF2 (rs149483638)	1.06 (0.8–1.3)	0.61	1.38 (1.1–1.8) ^a	0.014	1.1 (0.9–1.4)	0.44	1.56 (1.2–2) ^a	0.0010
INS (rs689)	1.09 (0.8–1.4)	0.52	1.63 (1.2–2.1) ^a	0.0003	1.23 (1–1.6) ^a	0.11	1.43 (1.1–1.9) ^a	0.012
KCNQ1 (rs2237897)	1.31 (1.1–1.6)	0.016	1.97 (1.5–2.5) ^a	< 0.0001	1.09 (0.9–1.4)	0.46	1.56 (1.2–2) ^a	0.0002
<i>CDKN1C</i> (rs163168)	1.36 (1.1–1.7) ^a	0.0043	1.82 (1.4–2.3) ^a	< 0.0001	1.05 (0.8–1.3)	0.64	1.45 (1.2–1.8) ^a	0.0015
SLC22A18 (rs450208)	1.46 (1.2–1.9) ^a	0.0014	1.27 (1–1.6)	0.053	1.38 (1.1–1.8) ^a	0.0092	1.36 (1.1–1.8)	0.015
Group 2								
IGF2BP2	1.16 (0.9–1.5)	0.26	1.65 (1.2–2.2) ^a	0.0007	1.09 (0.8–1.4)	0.54	1.37 (1–1.9)	0.042

total population (N = 4040 chromosomes).

	(rs4402960)								
	TCF7L2	1.22 (0.9–1.6) ^a	0.15	2.21 (1.6–3) ^a	< 0.0001	1.15 (0.9–1.5)	0.34	1.83 (1.3–2.5) ^a	0.0003
	(rs7903146)								
	CDKN2A	1.47 (1–2.2) ^a	0.049	0.92 (0.6–1.3)	0.65	1.07 (0.7–1.5)	0.73	1.08 (0.7–1.6)	0.72
	(rs10811661)								
	SLC30A8	1.31 (1–1.6) ^a	0.018	1.43 (1.1–1.8) ^a	0.0034	0.95 (0.7–1.2)	0.65	0.96 (0.7–1.2)	0.77
	(rs3802177)								
	HNF1A	1 92 (0 4-9 5)	0.43	1.97 (0.5–7.9)	0.34	2.85 (0.6–12.8) ^a	0.17	1.53 (0.3–6.9)	0.58
	(rs483353044)	1.52 (0.4 5.5)							
	WFS1	1 08 (0 8–1 4)	0.52	1.3 (1–1.7) ^a	0.065	0.99 (0.8–1.3)	0.95	0 99 (0 8–1 3)	0.94
	(rs4458523)	1.00 (0.0-1.4)	0.02		0.000		0.00		
	HMG20A	0.97 (0.8–1.2)	0.81	1.04 (0.8–1.3)	0.73	0.87 (0.7–1.1) ^a	0.19	0.88 (0.7–1.1) ^a	0.27
	(rs1005752)								
Gr	oup 3								
	SLC16A11	1.51 (1.2–1.9) ^a	< 0.0001	1.34 (1.1–1.7) ^a	0.011	1.24 (1–1.5) ^a	0.048	1.14 (0.9–1.4) ^a	0.27
	(rs75493593)							()	
	<i>IRS1</i> (rs1801278)	0.58 (0.3–1.2)	0.14	0.94 (0.5–1.9)	0.87	1.21 (0.7–2.2)	0.53	1.35 (0.7–2.6)	0.38
	FABP2	0.89 (0.7–1.1)	0.34	1.23 (1–1.6)	0.11	0.93 (0.7–1.2)	0.57	0.93 (0.7–1.2)	0.60
	(rs1799883)	0.09 (0.7-1.1)							

Sum of univariate R ²	0.056		0.14		0.02		0.079	
No. SNPs	9		12		4		10	
(rs4984636)	0.09 (0.0-1.2)	0.43	0.97 (0.7-1.4)	0.00	0.54 (0.4-0.0)	0.0022	0.37 (0.7-1.4)	0.07
CACNA1H	0.89 (0.6_1.2)	0.49	0.97 (0.7_1.4)	0.86	0 54 (0 4_0 8) ^a	0 0022	0.97 (0.7_1.4)	0.87
(rs6577691)	0.9 (0.7–1.2)	0.52	0.73 (0.5–1) ^a	0.083	1.02 (0.7–1.4)	0.91	0.68 (0.5–1) ^a	0.046
KHDRBS3								
(rs10261386)	0.95 (0.8–1.2)	0.62	1.1 (0.9–1.4)	0.42	0.94 (0.8–1.2)	0.61	1.23 (1–1.5)	0.088
CPED1								
(rs2070744)	0.71 (0.5–1)ª	0.028	0.86 (0.6–1.2)ª	0.38	0.85 (0.6–1.1)	0.28	0.99 (0.7–1.4)	0.96
NOS3		0.000		0.00		0.00		0.00
IL6 (rs1800795)	0.8 (0.5–1.2)	0.25	1.02 (0.7–1.6)	0.94	0.82 (0.6–1.2)	0.32	1.67 (1.1–2.5) ^a	0.0093
Group 4								
(rs10511567)	1.28 (1–1.6) [°]	0.029	0.76 (0.6–1) [°]	0.036	1.16 (0.9–1.5)°	0.22	0.9 (0.7–1.1)	0.39
PTPRD								
(rs1799999)	1.36 (1.1–1.7) ^a	0.0061	0.83 (0.6–1.1)	0.14	1.25 (1–1.6) ^a	0.060	0.94 (0.7–1.2)	0.64
PPP1R3A								
(rs7607759)	0.76 (0.5–1.2) ^a	0.23	1.06 (0.6–1.8)	0.83	1.17 (0.8–1.8)	0.46	1.26 (0.8–2.1)	0.37
CAPN10								

- 853 Abbreviations: CI, confidence interval; OR, odds ratio; R², variability of T2D explained by these genes; SNP, single nucleotide polymorphism; ULR,
- 854 univariate logistic regression.
- ^aIndicates SNPs that remain in the multivariate model.

GRCh38 chromosome 11p15.5 (*IGF2-INS-TH-KCNQ1-SLC22A18*)





Sex and age of T2D presentation



Sex and age of T2D presentation





Parental history of diabetes

Frequency (%)





В





Figure 5A



В













No. of risk alleles 0